doi: 10.1111/1753-0407.12891 Summary Keywords diabetic kidney disease, diabetic nephropathy, GLP-1 receptor agonists, liraglutide, semaglutide, dulaglutide Citation Kawanami D and Takashi Y (2020) GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
95% CI, 1.18 to 1.77), absent for liraglutide, especially in patients concurrently using antidepressants (ROR, 4.45
A) Belle Vies Medically Assisted Weight Management program aims for individuals to lose weight slowly and steadily, at the lowest possible dosage of the medication
According to the CDC, the adult obesity rate in the United States was 41.9% in 2017, and about one in 10 people in the United States have Type 2 diabetes